Vildagliptin shows diabetes benefits but raises CV concerns

05/28/2013 | MedPage Today (free registration)

A study presented at the Heart Failure Congress found type 2 diabetes patients with heart failure who took vildagliptin attained lower A1C levels at 16 weeks compared with those in the placebo group. However, researchers noted higher rates of cardiovascular and all-cause mortality in vildagliptin-treated patients.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN